Intelligent Target Selection for Bispecific Antibody Drug Conjugates

Our focus is on identifying new target combinations for cis-bispecific antibody drug conjugates (ADCs).

Promatix is developing innovative new classes of cancer therapies using bispecific antibodies.

Developing a Pipeline of Novel Bispecific ADCs to Treat Solid Tumours

Driven by proteomic analysis of all membrane proteins – the surfaceome – in normal and cancer tissue from patients.
We are exemplifying our platform by developing a pipeline of novel bispecific ADCs, with a lead program in colorectal cancer (CRC). We have a catalogue of bispecific assets with novel pairings tuned for eighteen common types of cancer identified using a combination of proprietary algorithms.

Our Approach

We use bispecific antibodies to improve tumour selectivity and therapeutic index by exploiting hybrid avidity.

Promatix Platform Changes the Landscape of Target Pair Selection for ADCs

The Promatix platform allows a systematic search for optimum combinations of cancer surface markers for cis-bispecific targeting of tumours – where both markers are present on the cancer cells. This “AND gating” approach dramatically reduces off-tumour toxicity while dramatically enhancing the range of targets and indications for ADCs. To date, the Promatix platform has identified >2,000 potential cis-bispecific combinations that meet strict criteria of differential cancer expression expected to optimise therapeutic index outcomes.

Platform

TxPro

A cancer proteomics database with comprehensive coverage of surface proteins across a wide range of cancer types.

CipherPro

A proprietary set of algorithms for systematic mining of target antigen pairs to enhance tumour specificity and therapeutic index.

AviPro

A proprietary in silico system for fine-tuning bispecific antibody affinities to maximise the therapeutic index.

BiPro

A rapid functional analysis pipeline based on a modular molecular framework to support selection of bispecific lead assets.

Promatix cis-bispecific ADC Pipeline

Advancing multiple therapeutics based on internal platform. First development candidate and validation of additional programs in 2026.

Latest News

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Non-dilutive Biomedical Catalyst funding from Innovate UK will support the advancement of Promatix’s lead cis-bispecific antibody-drug conjugate (ADC), PBS293-exatecan, towards development candidate nomination Award funds ...

Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026

Scarcity of truly tumour-selective targets remains a key limitation in ADC development, restricting delivery of safe and effective next-generation therapies Promatix’s integrated TxPro + CipherPro ...

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug ...

Resources

Overcoming the Limited Monospecific Target Landscape in Cancer via Discovery of Tumor-Selective AND- and OR-Gate Bispecifics

Hybrid Avidity–Gated EGFR x EphA2 Bispecific ADC Demonstrates Potent Anti-Tumour Efficacy while Sparing Keratinocytes

Management Team

Dr. Mick Hunter

CEO

Dr. Mark Edwards

CTO

Dr. Roy Pettipher

CSO

Lorna Collings

CFO

Dr. Shan Vinall

Project Manager

Dr. Katherine Vousden

Vice President, Research

Dr. Daniel Holdbrook

Principal Data Scientist

Richard Onyett

Business Development Director

Bruce Goldsmith

Advisor, Operating Partner, ALSA Ventures

Board

Alek Safarian

Non-Executive Director

Dr. Robert Balfour

Non-Executive Director

Dr. Graeme Martin

Executive Chairman

Advisory Team

Dr. Rakesh Dixit

President & CEO, Bionavigen

Dr. Andreas Drepps

SrVP and Global Head Drug Development Unit ICON plc

Dr. Simon Chivers

Consultant Toxicologist

Dr. Mike Mulkerrin

Managing Director, Sage Biodevelopment LLC

Peter Ruscoe

Partner at Sagittarius IP

Prof. Sir Alex Markham

Professor of Medicine

Prof. Jyoti Choudhary

Professor of Functional Proteomics

Prof. Gerard Evans, FRS

Professor of Cancer Biology

Dr. Mick Hunter

CEO

Mick is a co-founder of Promatix and has over 40 years biotech experience spanning concept to clinic for multiple IND candidates across a range of therapeutic indications including management of process development and GMP biologics production. He has held senior R&D executive positions at GD Searle, Atopix, Oxagen, British Biotech. He was the CSO of Atopix, sold to Chiesi in 2016, and founder and CEO of Orca Pharmaceuticals, whose ROR gamma program was licensed to AstraZeneca and to Brickell Biotech. More recently Mick was Entrepreneur in Residence at Evotec. He holds a PhD in Molecular Biology and Genetics from the University of Nottingham.

Dr. Mark Edwards

CTO

Mark is a co-founder of Promatix and has a 40-year background in applying protein engineering to drug discovery and development. He previously held positions at Searle, PA Technology, British Biotech and was the founding Director at Oxagen. Prior to joining Promatix, he was as a consultant working with start-ups on a wide range of products ranging from antibody therapies to antibiotic resistance and vaccines. He holds a BA in Biochemistry and DPhil in bacterial gene expression from Oxford.

Dr. Roy Pettipher

CSO

Roy is a co-founder of Promatix with over 30 years of industry experience in anti-inflammatory and oncology drug discovery and development. He is the founder and CSO at Orca Pharmaceuticals, a program licensed to AstraZeneca and has previously served as the research director at Atopix, which was sold to Chiesi in in 2016. He has also held senior R&D executive positions in biotech (Oxagen & AdoRx)and Pharma(Pfizer & Wellcome). Roy holds a PhD in Pharmacology from the University of London.

Lorna Collings

CFO

Lorna has more than twenty years of experience in private equity and venture capital with roles at EQT, Hermes GPE, Citco, Coller Capital, Ariadne Capital, Actis and BancBoston Capital. She holds a BA in Applied Psychology and is registered with the Chartered Institute of Management Accountants (ACMA).

Dr. Shan Vinall

Project Manager

Shan has over 20 years biotech experience in drug discovery and development. She has previously held project management positions at Atopix and Oxagen where she gained extensive experience in the management of outsourced preclinical and clinical development studies, documentation, project planning and budgeting. Shan holds a BSc in Biochemistry and a PhD in Intracellular signalling.

Dr. Katherine Vousden

Vice President, Research

Katherine is a proven leader in biologics discovery, with 25 years experience across biotech, biopharm and service organisations where she has built an extensive portfolio of candidate biologics in multiple disease areas. She has had significant strategic, project and group leadership roles at MedImmune/ AstraZeneca, Charles River and most recently held the position of site lead for AbCellera’s UK-based laboratory. Katherine holds a PhD in Genetics from the University of Leicester.

Dr. Daniel Holdbrook

Principal Data Scientist

Daniel currently leads efforts in applying data analytics, proteomics, and computational modelling to target identification and drug discovery. He has 16 years of experience in these areas and has worked at prestigious research institutions in the UK and Singapore. Additionally, he has extensive experience in developing ‘omics’ solutions within biotech start-up companies. Daniel holds a BSc in Biochemistry, an MSc in Bioinformatics, and a PhD in Computational Biochemistry.

Richard Onyett

Business Development Director

Richard Onyett, Business Development Director has worked with Promatix since Autumn 2025 to lead outreach with regard to commercial partnerships and licensing of technology and/or product assets. Prior to joining Promatix he was V.P. Business Development at ADC Therapeutics from 2012 until late 2024. Prior to that he served as Head of Business Development for Spirogen Ltd 2011 to 2012 and Oxagen Limited from 2006 to 2011. Richard led the business development programme at KuDOS Limited which resulted in the sale of the company to AstraZeneca (2001-2006). Prior to this Richard served as Head of Business and Corporate at several biotech companies and for two major pharma companies in marketing and business development roles.

Bruce Goldsmith

Advisor, Operating Partner, ALSA Ventures

Bruce has a strong background in Pharma and Biotech leadership over the past 25 years. He held progressively senior roles at Pharma and Biotech companies, including Johnson & Johnson, Allos Therapeutics and Lycera Corp. Following this experience, he joined Deerfield Healthcare as a Venture Partner and led a new company creation as CEO. He then joined Passage Bio as CEO leading an IPO and advancing four programs through IND. Throughout his career Bruce has led business development deals, strategy and operations. Bruce holds a PhD in Biology and an MBA.

Alek Safarian

Non-Executive Director

Alek has a diverse background in drug development spanning more than thirty years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US-based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney-based contract research organisation working with hundreds of clinical stage biotech companies over a twenty-one year period. Alek holds a BPharm and an MBA from the University of Sydney.

Dr. Robert Balfour

Non-Executive Director

Robert has a successful background in venture capital and Big Pharma, with companies such as GSK and Eli Lilly. He is a passionate start-up entrepeneur with experience in university technology transfer. Robert holds a BSc in Physiology and a PhD in Neurophysiology.

Dr. Graeme Martin

Executive Chairman

Graeme is a Pharmaceutical industry veteran and life-science venture capitalist with over three decades of innovative therapeutic R&D experience with Wellcome, GlaxoWellcome, Roche and Takeda that produced 4 IND submissions. He was the preclinical lead for the development of Zomig for migraine acute treatment. He also has two decades of life-science investment experience, having built and led the corporate venture unit of Takeda Pharmaceutical Company.  He currently serves strategic advisory and Board roles with private stage biotechnology companies and life science venture capital funds (ALSA Ventures; Harrington Discovery Institute) in the UK and USA, and was Chair of DJS Antibodies, acquired by AbbVie in 2022.